Avoro Capital Advisors LLC Uni Qure N.V. Transaction History

Avoro Capital Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$35.35 - $50.67 $61.9 Million - $88.7 Million	-1,750,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$35.98 - $47.66 $9 Million - $11.9 Million	250,000 Added 16.67%	1,750,000 $64.5 Million
Q2 2020 Aug 14, 2020	SELL	$45.06 - $67.74 $6.76 Million - $10.2 Million	-150,000 Reduced 9.09%	1,500,000 $67.6 Million
Q1 2020 May 15, 2020	SELL	$40.01 - $73.97 $2 Million - $3.7 Million	-50,000 Reduced 2.94%	1,650,000 $78.3 Million
Q4 2019 Feb 14, 2020	BUY	$37.13 - $74.62 $49.6 Million - $99.6 Million	1,335,000 Added 365.75%	1,700,000 $122 Million

Q3 2019 Nov 14, 2019	BUY	$39.36 - $76.8 $14.4 Million - $28 Million	365,000 New	365,000 $14.4 Million
Q2 2018 Aug 14, 2018	SELL	$21.96 - $39.94 $1.49 Million - $2.71 Million	-67,758 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$17.1 - $26.61 $1.16 Million - $1.8 Million	67,758 New	67,758 $1.59 Million

148

34.1M

1.07M

603K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $209M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Avoro Capital Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Avoro Capital Advisors LLC with notifications on news.